As pan-HER inhibitors have shown significant antitumor effects in vitro as well as in xenograft model of HER2-positive gastric cancer [55], the efficacy and safety of dacomitinib, an irreversible pan-HER tyrosine kinase inhibitor, was investigated in advanced gastric cancer patients. This evidence concerns the gene ERBB2 and gastric cancer.